Table 1 Baseline characteristics of the patients
Quantitative parameters | Total (n = 40) | RI < 0.5 (n = 12) | RI ≥ 0.5 (n = 28) | p value |
|---|---|---|---|---|
Median (IQR) | Median (IQR) | Median (IQR) | ||
Age (year) | 58 (47 to 65) | 57 (52 to 64) | 59 (43 to 67) | 0.896 |
Weight (kg) | 98 (90 to 110) | 92 (100 to 110) | 95 (86 to 114) | 0.475 |
Height (cm) | 179 (170 to 183) | 170 (175 to 180) | 180 (166 to 185) | 0.224 |
SAPS-II at admission | 43 (36 to 52) | 39 (36 to 53) | 43 (34 to 52) | 0.899 |
SARS-CoV-2 PCR (ct) | 31 (28 to 37) | 31 (28 to 36) | 32 (27 to 37) | 0.965 |
Days of invasive ventilation before RI (d) | 2 (1 to 11) | 4 (1 to 10) | 2 (1 to 13) | 0.984 |
PEEP before RI (mbar) | 14 (12 to 15) | 14 (13 to 15) | 15 (12 to 15) | 0.942 |
Compliance before RI (ml mbar−1) | 30 (21 to 40) | 17 (13 to 36) | 32 (26 to 42) | 0.005 |
Initial PF ratio (prior to vvECMO) | 82 (68 to 116) | 75 (60 to 88) | 104 (72 to 122) | 0.058 |
Qualitative parameters | Total (n = 40) | RI < 0.5 (n = 12) | RI ≥ 0.5 (n = 28) | p value |
|---|---|---|---|---|
% (n) | % (n) | % (n) | ||
Gender male | 75.0 (30) | 66.7 (8) | 78.6 (22) | 0.671 |
vvECMO therapy | 75.0 (30) | 91.7 (11) | 67.9 (19) | 0.247 |